alcoholic prolamine solution

Subscribe to Selected New Research on alcoholic prolamine solution

89 relevant articles (13 outcomes, 8 trials/studies) found for this Bio-Agent

Description: a prolaminacid solution containing zein, diatrizoate sodium tetrahydrate, poppy-seed oil & propylene glycol; polymerizes in an aqueous medium in approx 15 min; used in abdominal surgery for occluding the pancreatic duct system

Also Known As:

Ethibloc; ethybloc; zeine-alcohol suspension

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Laberge, Louise: 1 article (05/2006)
2.	Bütter, Andreana: 1 article (05/2006)
3.	Yazbeck, Salam: 1 article (05/2006)
4.	Emran, Mohammad Ali: 1 article (05/2006)
5.	Dubois, Josée: 1 article (05/2006)
6.	Al-Jazaeri, Ayman: 1 article (05/2006)
7.	de Gauzy, Jérôme Sales: 1 article (09/2005)
8.	Cahuzac, Jean Philippe: 1 article (09/2005)
9.	Accadbled, Franck: 1 article (09/2005)
10.	Mascard, Eric: 1 article (09/2005)

Related Diseases

1.	Lymphangioma (Cavernous Lymphangioma) 10/01/2000 - "In our experience, Ethibloc is particularly appropriate for the treatment of large lymphangiomas." 10/01/2000 - "It materialized as an Ethibloc exteriorization among 5 patients suffering from venous angiomas and 3 patients suffering from lymphangiomas and as an inflammatory lump for 2 venous angiomas carriers and for 4 lymphangiomas carriers. " 09/01/1997 - "The most frequent complication was leakage of Ethibloc without important sequelae in 10 of the 14 lymphangiomas. " 09/01/1997 - "MATERIALS AND METHODS: Fourteen patients with macrocystic and mixed lymphangiomas were treated with use of Ethibloc as a sclerosing agent. " 01/01/1997 - "POPULATION AND METHODS: Between 1987 and 1993, 20 patients with a superficial macrocystic lymphangioma were treated by percutaneous injection of Ethibloc in order to reduce the volume of the CL, with a minimum follow-up of 1 year. " Order ALL the reference details at left...
2.	Chronic Pancreatitis 01/01/1998 - "METHODS AND RESULTS: To achieve the burned out state of chronic pancreatitis, occlusion of the pancreatic duct was first attempted by our team with Ethibloc at ERCP. " 01/01/1989 - "Alcohol-induced chronic pancreatitis in rats after temporary occlusion of biliopancreatic ducts with Ethibloc." 01/01/1987 - "Altogether, Whipple's procedure plus intraoperative Ethibloc occlusion of the residual pancreatic duct system seems suitable for termination of the inflammatory process and thus preservation of residual endocrine pancreatic function in chronic pancreatitis." 12/17/1981 - "On the basis of a standardized, improved surgical technique, and the introduction of pancreatic ductal occlusion with Ethibloc to prevent recurrence, we have succeeded in achieving a considerable improvement in the early and late results of partial duodenopancreatectomy in the treatment of chronic pancreatitis; this improvement is reflected in a marked reduction in the surgical mortality rate from, formerly, 8.2 in 49 to 0.86% in 116 operations, together with, to date, very good late results, with freedom from symptoms in 90.2%, a recurrence rate of 1.1%, and a postoperative increase in weight of, on average, 7.8 kg in 85% of the cases so treated." 04/01/1990 - "We conclude that partial pancreaticoduodenectomy with occlusion of the pancreatic duct with Ethibloc is the procedure of choice in severe chronic pancreatitis mainly affecting the head of the gland." Order ALL the reference details at left...
3.	Atrophy 06/01/1990 - "In a prospective follow-up study of 23 patients, Ethibloc duct occlusion was shown to be highly effective in inducing controlled atrophy of the gland and thereby terminating the inflammatory process. " 01/01/1983 - "Consequently, Ethibloc duct occlusion does not seem to be a superior alternative to other methods of producing exocrine atrophy in organs intended for transplantation." 11/01/1989 - "We conclude that Ethibloc occlusion is highly effective in inducing complete exocrine atrophy, thus abolishing the inflammatory process and preventing relapses of chronic pancreatitis and preserving the endocrine function from further impairment. " 04/01/1990 - "Partial pancreaticoduodenectomy with occlusion of the remaining tail of the pancreas with Ethibloc to induce rapid exocrine atrophy was introduced by us in January 1978 for the treatment of severe chronic pancreatitis affecting the head of the gland. " 11/01/1989 - "Partial duodenopancreatectomy and occlusion of the remaining ductal system by Ethibloc to induce rapid exocrine atrophy for treatment of severe chronic cephalic pancreatitis was introduced in our department in January of 1978. " Order ALL the reference details at left...
4.	Neoplasms (Cancer) 11/01/2006 - "Injection of sclerosing agent (Ethibloc) was indicated in 4 cases because of the volume of the tumor. " 01/01/1989 - "Contrary to other angioocclusive treatment modalities, the concept of capillary occlusion with Ethibloc seems to achieve total tumor destruction." 10/01/1984 - "[Palliative embolization of kidney tumors using iodol-marked Ethibloc]" 09/01/1980 - "The second embolization with Ethibloc provoked a regression of the tumor." 01/01/1988 - "Two patients with abdominal hemorrhage from a hepatic tumor underwent transcatheter embolization using Ethibloc. " Order ALL the reference details at left...
5.	Aneurysmal Bone Cysts (Aneurysmal Bone Cyst) 10/01/2003 - "The purpose of this study is to report the results of direct Ethibloc injection in primary aneurysmal bone cyst (ABC) in children. " 05/01/2006 - "Nevertheless, the complications encountered in some series after percutaneous embolization of aneurysmal bone cyst with Ethibloc should encourage the use of Ethibloc injection not as an initial treatment but as a reliable alternative to surgery." 09/01/2005 - "Direct ethibloc injection of aneurysmal bone cysts." 09/01/2005 - "Ethibloc injection may be performed as a primary treatment of aneurysmal bone cysts if the technique is followed with precision." 09/01/2005 - "The effects of percutaneous Ethibloc (Ethicon/Johnson & Johnson, St-Stevens-Woluwe, Belgium) injection into primary aneurysmal bone cysts were analysed. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Iodized Oil (Lipiodol)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Ethanol (Ethyl Alcohol)
4.	Mitomycin (Mitomycin-C)
5.	Silicones
6.	Phenylpropanolamine (Dexatrim)
7.	Glucose (Dextrose)
8.	Hydrogel
9.	Fibrin Tissue Adhesive (Fibrin Sealant)
10.	Biological Markers (Surrogate Marker)

Related Therapies and Procedures

1.	Sclerotherapy
2.	Ligation
3.	Nephrectomy
4.	Pancreaticoduodenectomy
5.	Lasers (Laser)

Best Treatments:
Research Summary Report
on Lymphangioma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 34 Outcomes
Top 103 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>